Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13976379 | 0.90 | BCHE (0.44) | L3MBTL1NPSR1TDP1ATMMAPT | |
| SCHEMBL611824 | 0.88 | STK17B (0.47) | L3MBTL1NPSR1TDP1ATMMAPT | |
| SCHEMBL10047095 | 0.77 | BCHE (0.42) | L3MBTL1NPSR1TDP1ATMMAPT | |
| SCHEMBL20508956 | 0.74 | TDP1 (0.37) | L3MBTL1NPSR1TDP1MAPTRECQL | |
| SCHEMBL6801342 | 0.73 | L3MBTL1 (0.42) | L3MBTL1NPSR1TDP1MAPTPOLB | |
| SCHEMBL13836023 | 0.73 | CDK1 (0.39) | KMT2A | |
| SCHEMBL10047120 | 0.72 | L3MBTL1 (0.38) | L3MBTL1MEN1KMT2APOLB | |
| SCHEMBL18176950 | 0.71 | BCHE (0.44) | L3MBTL1NPSR1TDP1ATMMAPT | |
| SCHEMBL10047089 | 0.71 | ADORA2A (0.40) | — | |
| SCHEMBL611825 | 0.71 | STK17B (0.47) | L3MBTL1NPSR1TDP1ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895734-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8884008-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-11 | — | — | US | disclosed |
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-10-30 | — | — | US | disclosed |
| US-8859766-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-10-14 | — | — | US | disclosed |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-8680253-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2012-02-16 | — | — | US | disclosed |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | L3MBTL1 1049/4885NPSR1 548/4885TDP1 823/4885 |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | L3MBTL1 1049/4885NPSR1 548/4885TDP1 823/4885 |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | L3MBTL1 1049/4885NPSR1 548/4885TDP1 823/4885 |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | L3MBTL1 1049/4885NPSR1 548/4885TDP1 823/4885 |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | L3MBTL1 1049/4885NPSR1 548/4885TDP1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.